Table 1 Characteristics of randomized, double-blind, placebo-controlled clinical trials included in the clinical test sample.
From: Polygenic heterogeneity in antidepressant treatment and placebo response
ClinicalTrials.gov Identifier | Treatment length, weeks | Vortioxetine dose, mg | Scales | N | Female, % | Age, mean (SD) | Baseline MADRS, mean (SD) |
|---|---|---|---|---|---|---|---|
NCT01422213 | 8 | 10, 20 | MADRS, PDQ | 184 | 63.04 | 46.22 (11.98) | 31.75 (3.77) |
NCT00839423 | 6 | 5,10 | MADRS, HAM-A | 136 | 66.18 | 42.42 (12.04) | 33.74 (2.57) |
NCT00635219 | 8 | 2.5, 5, 10 | MADRS, HAM-A | 254 | 70.08 | 45.70 (12.20) | 31.69 (3.60) |
NCT01140906 | 8 | 15, 20 | MADRS, HAM-A | 233 | 64.81 | 46.79 (13.60) | 31.23 (3.34) |
NCT01153009 | 8 | 15, 20 | MADRS, HAM-A | 196 | 77.04 | 43.77 (12.71) | 31.92 (4.20) |
NCT01163266 | 8 | 10, 20 | MADRS, HAM-A, CPFQ | 178 | 74.72 | 43.42 (12.77) | 32.05 (3.78) |
NCT01179516 | 8 | 10, 15 | MADRS, HAM-A, CPFQ | 183 | 69.95 | 45.95 (12.30) | 33.59 (4.03) |
Total | 6–8 | 2.5, 5, 10, 15, 20 | MADRS, PDQ, HAM-A, CPFQ | 1364 | 69.43 | 45.09 (12.62) | 32.16 (3.76) |
